RxDoctor Payments Data

Charles Calvert, DO

Family Medicine · Coppell, TXNPI 1659592012

Payments from drug & device makers

$6,196in general payments, 2019–2025

Across 375 payments — averaging $16.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$733
  • AbbVie$624
  • Amarin Pharma, Inc.$516
  • AstraZeneca$446
  • Lilly USA, LLC$407
  • Amgen$348
  • plus $3K from 39 others

What the payments were for

  • Consulting fees$501%
  • Food & beverage$6,13899%
  • Education$80%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,196 in reported general payments places this provider in the 85th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$66,989
Medicare patients
171
Services billed
1,355

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide48$69,954
Synjardy XrEmpagliflozin/Metformin Hcl38$57,314
EliquisApixaban37$47,822
XareltoRivaroxaban30$46,536
MounjaroTirzepatide30$46,059
RybelsusSemaglutide16$35,563
FarxigaDapagliflozin Propanediol24$33,081
ProliaDenosumab16$28,319
Xigduo XrDapaglifloz Propaned/Metformin24$28,193
Soliqua 100-33Insulin Glargine/Lixisenatide12$18,626
JardianceEmpagliflozin14$18,274
Trelegy ElliptaFluticasone/Umeclidin/Vilanter18$17,726
Fluticasone-SalmeterolFluticasone Propion/Salmeterol22$5,416
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen38$3,233
Lantus SolostarInsulin Glargine,hum.Rec.Anlog21$2,862

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$733$105,51764 claims
Boehringer IngelheimSynjardy Xr, Jardiance$168$75,58852 claims
PfizerEliquis$162$47,82237 claims
Johnson & JohnsonXarelto$258$46,53630 claims
Lilly USA, LLCMounjaro$407$46,05930 claims
AstraZenecaFarxiga$446$33,08124 claims
AmgenProlia$348$28,31916 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$67$18,62612 claims
GSKTrelegy Ellipta$124$17,72618 claims
AbbVieSynthroid$624$1,36120 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Coppell

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →